Y-Intercept (HK)’s Bio-Rad Laboratories Class A BIO Stock Holding History

Y-Intercept (HK)’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.43M	Buy	+3,780	New	+$1.32M	0.03%	801
2025 Q2	–	Sell	-847	Closed	-$206K	–	1639
2025 Q1	$206K	Buy	+847	New	+$255K	0.01%	1046
2024 Q4	–	Sell	-6,679	Closed	-$2.23M	–	1200
2024 Q3	$2.23M	Buy	+6,679	New	+$2.12M	0.14%	183
2023 Q4	–	Sell	-3,150	Closed	-$1.13M	–	1237
2023 Q3	$1.13M	Buy	+3,150	New	+$1.22M	0.11%	275
2023 Q2	–	Sell	-1,047	Closed	-$502K	–	1279
2023 Q1	$502K	Buy	+1,047	New	+$490K	0.06%	528
2022 Q4	–	Sell	-3,793	Closed	-$1.58M	–	1008
2022 Q3	$1.58M	Buy	+3,793	New	+$1.89M	0.16%	192
2022 Q2	–	Sell	-1,871	Closed	-$1.05M	–	870
2022 Q1	$1.05M	Buy	+1,871	New	+$1.13M	0.24%	103
2021 Q4	–	Sell	-2,219	Closed	-$1.66M	–	588
2021 Q3	$1.66M	Buy	+2,219	New	+$1.66M	0.3%	92
2021 Q2	–	Sell	-585	Closed	-$330K	–	629
2021 Q1	$330K	Buy	+585	New	+$346K	0.09%	369

Other funds holding BIO

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return

Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Boston Trust Walden Boston, Massachusetts $12.4B AUM 21.62% 1-Year Est. Return

Hosking Partners London, United Kingdom $2.81B AUM 67.07% 1-Year Est. Return

Exchange Traded Concepts Oklahoma City, Oklahoma $25.3B AUM 51.52% 1-Year Est. Return

Y-Intercept (HK)'s BIO Position: Q3 2026 in Review

Y-Intercept (HK) opened a new position in Bio-Rad Laboratories Class A (BIO) in Q3 2026: 3,780 shares worth $1.43M. The stake represents 0.03% of the portfolio and ranks #801 among its holdings. This is a return to the name: Y-Intercept (HK) previously reported a position in BIO as recently as Q1 2025.

Y-Intercept (HK) first reported a position in BIO in Q1 2021 and has held it in 9 quarters since. The position peaked at $2.23M in Q3 2024. 195 funds tracked by Wall St. Rank hold BIO as of Q3 2026.

Y-Intercept (HK) held 3,780 shares of Bio-Rad Laboratories Class A worth $1.43M as of Q3 2026.
Bio-Rad Laboratories Class A was a new Y-Intercept (HK) position in Q3 2026.
Bio-Rad Laboratories Class A made up 0.03% of Y-Intercept (HK)'s portfolio in Q3 2026, its #801 holding.
Y-Intercept (HK) first reported a position in Bio-Rad Laboratories Class A in Q1 2021 and has held it in 9 quarters since.
Y-Intercept (HK)'s Bio-Rad Laboratories Class A position peaked at $2.23M in Q3 2024.
195 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2026.

Based on Y-Intercept (HK)'s 13F filing for Q3 2026, filed 16 Oct 2026.